AJMC December 15, 2025
Key Takeaways
Two-thirds of pharmaceutical companies did not proactively release the launch price of their medications from 2022 to 2024.
ABSTRACT
Objective: To examine how drug manufacturers disclosed prices for new molecular entities approved by the FDA between 2022 and 2024.
Study Design: Retrospective study.
Methods: We included drugs approved through new drug applications or biologics license applications, excluding imaging agents, vaccines, blood products, and drugs without an assigned National Drug Code. For each drug, we assessed whether pricing was disclosed proactively (ie, in news releases or earnings calls) or reactively (ie, in media reports citing the company without prior proactive disclosure). We sourced launch prices from public disclosures and California filings. We also...
Today's Sponsors
Today's Sponsor